Silencing RNA nanotherapy shows promise against pancreatic cancer

Despite advances in cancer survival, more than 90 percent of people with pancreatic cancer die within five years. Most patients with pancreatic tumors (and half of those with colorectal cancers) carry a mutation in the KRAS gene, which normally controls cell growth and death.<br />
<br /&gt …
Ingeniería
Enlace: Silencing RNA nanotherapy shows promise against pancreatic cancer